145
Participants
Start Date
September 15, 2020
Primary Completion Date
April 15, 2026
Study Completion Date
April 15, 2026
Datopotamab deruxtecan
Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)
KEYTRUDA®
Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
Carboplatin
Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)
Cisplatin
Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/m\^2)
National Taiwan University Hospital NTUH, Taipei
National Cheng Kung University Hospital NCKUH, Tainan City
Johns Hopkins Kimmel Cancer Center, Washington D.C.
Azienda Ospedaliera San Gerardo, Monza
Instituto Europeo Di Oncologica, Milan
Johns Hopkins Kimmel Cancer Center at Bayview, Baltimore
The Skip Viragh Outpatient Cancer Building, Baltimore
START Madrid - Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
(CIOCC-START) Hospital Universitario HM Sanchinarro, Madrid
Hospital Puerta de Hierro, Majadahonda
Mayo Clinic, Jacksonville
Chung Shan Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
Mayo Clinic, Rochester
NEXT Oncology, San Antonio
Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Struttura di Oncologia, Naples
Mayo Clinic, Scottsdale
Quantum Santa Fe, Santa Fe
City of Hope, Duarte
National Cancer Center Hospital East, Chiba
National Cancer Center Hospital, Tokyo
Showa Medical University Hospital, Tokyo
H. Vall Hebrón (Vall Hebron Institut de Oncologia - VHIO), Barcelona
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Daiichi Sankyo
INDUSTRY